Lundbeck raises guidance



H. Lundbeck A/S received an uplift in the first half year from two regulatory approvals and the strong performance of its new migraine prevention treatment Vyepti. As a result, the company has upgraded its financial guidance and now expects revenue to increase by 7% to 10% for the year. Overseeing this period of growth will be Charl van Zyl who has been named president and chief executive officer, effective 1 September. Mr van Zyl is an executive at UCB SA of Belgium. He will succeed Deborah Dunsire who has led the company since 2018.